N
CHRS icon

Natixis’s Coherus Oncology CHRS Stock Holding History

Natixis’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,500
Closed -$235K – 1126
2022
Q3 		$235K Buy
+24,500
New +$248K ﹤0.01% 964

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Natixis's CHRS Position: Q4 2022 in Review

Natixis sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 24,500 shares — an estimated $235K sold.

Natixis first reported a position in CHRS in Q3 2022 and held it in 1 quarter. The position peaked at $235K in Q3 2022. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Natixis reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Natixis sold 24,500 Coherus Oncology shares in Q4 2022, an estimated $235K.
  • Natixis first reported a position in Coherus Oncology in Q3 2022 and held it in 1 quarter.
  • Natixis's Coherus Oncology position peaked at $235K in Q3 2022.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.